It figures to be about a $30 stock in four years. Value Line seemingly had some lowball valuations on a stand-alone basis and I sure don't see why the combined companies with the cost savings and synergies would be worth less than the stand-alone lowball valuations.
Value Line sees PFE stand-alone as $160B at the end of 2012 and WYE at $90B. The $250 combined estimated market cap divided by about 8 billion shares comes to $31 per share.
I wonder what Catherine Arnold now thinks. It wasn't that long ago that she said Pfizer was worth $29 a share if it bought out WYE. At the time, WYE was at $42.50 so certainly she can't think that $50 is too much.